Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...

Anavex Life Sciences remains one of the few non-amyloid Alzheimer's drug developers. Find out why I rate AVXL stock as a Hold ...

Seoul Asan Medical Center said it started prescribing the early Alzheimer's disease drug "Leqembi" (generic name lecanemab) ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

December 2024 seems to be the month of skepticism for Biogen Inc ( NASDAQ:BIIB ), as this biotechnology company focusing on neurological and neurodegenerative diseases has received multiple downgrades ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...

China is the fourth major market in which the treatment, sold under the brand name Kisunla, has received approval after the ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

Dec 3 (Reuters) - Biogen (BIIB.O), opens new tab expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States in the near term, a company ...